Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

15.9%

766 terminated/withdrawn out of 4817 trials

Success Rate

81.7%

-4.8% vs industry average

Late-Stage Pipeline

26%

1229 trials in Phase 3/4

Results Transparency

62%

2142 of 3429 completed trials have results

Key Signals

231 recruiting2142 with results625 terminated141 withdrawn

Enrollment Performance

Analytics

Phase 1
1382(34.7%)
Phase 2
1082(27.1%)
Phase 3
784(19.7%)
Phase 4
445(11.2%)
N/A
274(6.9%)
Early Phase 1
20(0.5%)
3987Total
Phase 1(1382)
Phase 2(1082)
Phase 3(784)
Phase 4(445)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4817)

Showing 20 of 4817 trials
NCT05317416Phase 3Active Not Recruiting

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

Role: lead

NCT04606446Phase 2Recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

Role: lead

NCT03460977Phase 1Recruiting

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Role: lead

NCT04743141Phase 3Recruiting

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

Role: lead

NCT04649242Phase 3Recruiting

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

Role: lead

NCT06152575Phase 3Recruiting

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Role: lead

NCT06679140Phase 3Recruiting

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Role: lead

NCT05639647Phase 2Recruiting

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

Role: lead

NCT06057402Phase 4Recruiting

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Role: lead

NCT07062965Phase 3Recruiting

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Role: lead

NCT05070845Phase 2Recruiting

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

Role: lead

NCT06641466Phase 3Recruiting

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

Role: lead

NCT06629779Phase 3Recruiting

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Role: lead

NCT04355156Phase 2Completed

Axitinib Monotherapy With Early Dynamic Contrast Enhanced Ultrasound Monitoring in Chemorefractory Third Line Metastatic Colorectal Cancer

Role: collaborator

NCT05156398Phase 3Recruiting

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

Role: lead

NCT05623020Phase 3Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

Role: lead

NCT03059940Early Phase 1Active Not Recruiting

Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung Cancer

Role: collaborator

NCT07475806Phase 2Recruiting

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Role: collaborator

NCT04072952Phase 1Completed

A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Role: collaborator

NCT06297161Recruiting

A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).

Role: lead